First, the duration of treatment of previously untreated patients was kept as 2 years only. Although the risk of progression from latent TB infection (LTBI) to active TB is greatest in the first 2 years,2 in Southeast Asia, where TB burden is very high, the duration of follow-up is apparently much less. In countries like India, where the prevalence of LTBI (hence, positive IGRA or tuberculin skin test results) is very high, a follow-up of only 2 years for progression to active TB does not seem justified. This short follow-up period is probably sufficient for countries with a low TB burden. As a huge proportion of the population on the Southeast Asian subcontinent acquires TB infection in childhood only,3 it remains doubtful whether these tests can be used as a surrogate marker to predict the progression of TB infection.